Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1342 - Gene expression profiling of 21 genes in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat.

Resubmissions:
A subsequent application has been submitted, please refer to the resubmitted application 1342.1
Assessment No1342
Application NameGene expression profiling of 21 genes in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit
Assessment TypeSubmission Based Assessment
Description Of Medical ServiceThis is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.
Description Of Medical ConditionOutside Australia, this test is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.
Stage 2 – Suitability for Assessment7 November 2012
Stage 3 - 1st PASC
(Draft Protocol considered)
13 & 14 December 2012
Stage 3 – Release for Public Comment
(Consultation Protocol)
28 June 2013
PDF version Consultation Protocol (PDF 721 KB)
Word version Consultation Protocol (Word 496 KB)
Close for comments 19 July 2013
Stage 3 - 2nd PASC
(Final Protocol)
No second PASC required
PDF version Final Protocol (PDF 1158 KB)
Word version Final Protocol (Word 488 KB)
Stage 4 - Submission of Collated Evidence9 July 2013
Stage 5 - ESC evaluation10 and 11 October 2013
Stage 6 - MSAC Appraisal28 November 2013
Stage 6 - MSAC advicePDF version Public Summary Document (PDF 240 KB)
Word version Final Public Summary Document (Word 138 KB)

Resubmission: Please see Application 1342.1

Page currency, Latest update: 06 April, 2016